The Gut Bacteria Imbalance That Quietly Accelerates Liver Disease

When bacteria multiply out of control in the small intestine, the liver pays a steep price. A comprehensive review published in IntechOpen eBooks by Rashad Hasanov, Gulustan Babayeva, Esmira Abdullayeva, and Kamala Gasimova maps out how small intestinal bacterial overgrowth (SIBO), defined as more than 10^5 colony-forming units per milliliter in the small bowel, sets off a chain of inflammatory and metabolic events that appear to worsen chronic hepatitis. The research is still emerging, but the proposed mechanism is detailed enough to change how clinicians might think about gut health in liver disease patients.

How SIBO Drives Liver Inflammation Through the Gut-Liver Axis

The central pathway begins with a "leaky gut." SIBO disrupts the tight junctions between intestinal epithelial cells, allowing bacterial products, particularly lipopolysaccharide (LPS), a component of Gram-negative bacterial cell walls, to seep into the portal circulation that feeds directly into the liver. Once there, LPS binds to Toll-like receptor 4 (TLR4) on Kupffer cells, the liver's resident immune cells, triggering a signaling cascade through MyD88 and nuclear factor kappa B (NF-kB). The result is a surge of proinflammatory cytokines: tumor necrosis factor-alpha (TNF-a), interleukin-6 (IL-6), and interleukin-1 beta (IL-1b). Patients with SIBO show markedly higher circulating levels of these cytokines compared to those without it. This is not an isolated biochemical curiosity: dysfunctional gut microbiota and increased gut permeability allow toxic metabolites and bacteria to enter the liver, a dynamic now recognized as central to the pathogenesis of hepatitis and cirrhosis alike.

Fibrosis, Encephalopathy, and Other Complications in Liver Disease Patients

The inflammatory environment created by SIBO does not stay contained to early-stage injury. Chronic cytokine exposure activates hepatic stellate cells, the primary drivers of liver fibrosis, which begin producing collagen. Transforming growth factor-beta (TGF-b) is the key signaling molecule in this process. According to the review, fibrosis progression is more rapid in patients with SIBO than in those without it, and a meta-analysis of 34 case-control studies confirmed a significantly increased prevalence of SIBO in patients with chronic liver disease compared to healthy controls. Prevalence rises with disease severity, peaking in decompensated cirrhosis. Beyond fibrosis, SIBO increases ammonia production and other neurotoxic substances in the gut, worsening hepatic encephalopathy (HE), the cognitive dysfunction seen in advanced liver disease. The review notes that targeting bacterial overgrowth with rifaximin, a minimally absorbed antibiotic, can reduce both the frequency and severity of HE episodes. SIBO also raises susceptibility to dangerous infections such as spontaneous bacterial peritonitis and sepsis by facilitating microbial translocation into the bloodstream.

Metabolic Disruption: Insulin Resistance, Fat Accumulation, and Bile Acid Dysfunction

SIBO does not only inflame; it also rewires metabolism in ways that compound hepatic injury. The overgrowth impairs farnesoid X receptor (FXR) signaling, a nuclear receptor that normally regulates bile acid homeostasis. When FXR function is compromised, lipogenesis increases and insulin sensitivity falls. Inflammation simultaneously activates lipogenic transcription factors, including SREBP-1c, driving excess fatty acid and triglyceride synthesis in the liver. Adipose tissue dysfunction adds another layer: SIBO-associated changes in the gut microbiome appear to lower adiponectin (an anti-inflammatory adipokine) and elevate leptin. Meanwhile, short-chain fatty acids (SCFAs) like butyrate, which normally reinforce the gut barrier and dampen inflammation, are produced at dysregulated levels in SIBO. Taken together, these metabolic effects help explain why SIBO-positive patients with chronic hepatitis face compounding injury beyond what viral load alone would predict.

SIBO in Viral Hepatitis: HBV, HCV, and the Microbiome

Both major chronic viral hepatitis infections reshape the gut microbiome in ways that likely promote SIBO. In hepatitis B (HBV), the review identifies reduced populations of Bifidobacterium and Lactobacillus alongside expansion of opportunistic pathogens. Hepatitis C (HCV) is linked to decreased overall microbial diversity and growth of Proteobacteria. Impaired intestinal motility, reduced bile acid secretion, and portal hypertension, all common features of progressive viral hepatitis, each create conditions that favor bacterial overgrowth in the small bowel. Encouragingly, direct-acting antiviral (DAA) therapy for HCV has been associated with partial restoration of microbial diversity, though whether SIBO status directly affects treatment response to antivirals remains an open question.

Diagnostic Gaps and the Uncertain Road Ahead for SIBO Treatment

Despite the mechanistic clarity the review offers, the clinical picture has significant gaps. Diagnosing SIBO typically relies on breath tests, such as the glucose hydrogen breath test, which measures hydrogen or methane in exhaled air after a glucose load. These tests carry variable sensitivity and specificity and can be skewed by multiple confounders, making standardized diagnosis difficult. On the treatment side, rifaximin is the best-studied option, but many SIBO treatment studies lack control groups, and small randomized trials have reported conflicting results, leaving optimal regimens undefined. Probiotics show promise in modulating gut microbiota but optimal formulations and treatment durations are not yet established. The deeper causal question also remains unresolved: does SIBO accelerate liver disease, or does liver disease create the conditions for SIBO, or both? Microbiome-based therapeutics including probiotics, prebiotics, and synbiotics are being evaluated for managing complications of liver cirrhosis, and researchers recommend future trials incorporate metagenomic and metabolomic analysis to better untangle these relationships. Longitudinal studies that track SIBO status alongside liver disease progression are still needed before the field can move from mechanistic plausibility to firm clinical guidance.

Evidence rating

EMERGING — 75/100

Caveats:

• This is a narrative review, not an original study — it synthesizes existing literature rather than generating new data, so it cannot establish cause and effect on its own.
• Whether SIBO is a cause or a consequence of liver disease remains an open question; the direction of the relationship is not yet settled.
• Diagnostic methods for SIBO (e.g., breath tests) have variable sensitivity and specificity, which complicates interpretation across the studies reviewed.
• Funding source was not disclosed by the authors.

Narrative review chapter synthesizing clinical and mechanistic literature on SIBO and chronic liver disease. Presents no original data and cannot establish causation; causal direction between SIBO and liver disease progression remains debated in the underlying literature. Key mechanistic claims (LPS–TLR4–NF-κB pathway, fibrosis acceleration) are grounded in multiple prior studies but have not been independently replicated in a single unified trial.

References

1. Rashad Hasanov, Gulustan Babayeva, Esmira Abdullayeva and Kamala Gasimova (2026). Bacterial Overgrowth Syndrome and Chronic Hepatitis. Unresolved Issues in Chronic Hepatitis [Working Title]. https://doi.org/10.5772/intechopen.1016079
2. Jianpeng Wang, Xinyi Wang, Enba Zhuo, Bangjie Chen, Shixin Chan (2024). Gut‑liver axis in liver disease: From basic science to clinical treatment (Review). Molecular Medicine Reports. https://doi.org/10.3892/mmr.2024.13375
3. Ayesha Shah (2017). Systematic Review and Meta-Analysis: Prevalence of Small Intestinal Bacterial Overgrowth in Chronic Liver Disease. https://doi.org/10.26226/morressier.59a6b349d462b80290b5535b
4. Venkatesh Vaithiyam, Sanjeev Sachdeva, Payila Aneesh, et al. (2025). Small Intestinal Bacterial Overgrowth in Patients With Severe Alcoholic Hepatitis: Frequency and Predictors. Cureus. https://doi.org/10.7759/cureus.85516
5. Roman Maslennikov, Victoria Agarkova, Elena Poluektova, et al. (2026). Treatment of Small Intestinal Bacterial Overgrowth (SIBO) in Gastrointestinal, Hepatic, Endocrine, Neurological, and Postoperative Diseases: A Comprehensive Narrative Review. Medical Sciences. https://doi.org/10.3390/medsci14020300
6. (2017). Gut Microbiome-based Therapeutics in Liver Cirrhosis: Basic Consideration for the Next Step. Journal of Clinical and Translational Hepatology. https://doi.org/10.14218/jcth.2017.00008